Kaposi Sarcoma Market
Kaposi Sarcoma Market (Treatment - Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel - Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Press Release :
Kaposi Sarcoma Market: Snapshot
Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. The cancer usually appears as tumors on mucosal surfaces or on the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal KS cells cause brown, purple, or red blotches on the skin, called lesions.
The global Kaposi sarcoma market features a rising number of regional vendors commanding prominent shares in their respective regional territories. Owing to the looming patent expiries of several blockbuster drugs, the market is expected to witness the entry of several new companies producing generics. The situation also presents immense growth opportunities for leading companies with new drug formulations in the next few years.
Transparency Market Research states that the global Kaposi sarcoma market will exhibit a modest 2.2% CAGR over the period between 2016 and 2024, rising from a valuation of US$118.5 mn in 2015 to US$143.2 mn by 2024.
Chemotherapy Continues to Remain Most Preferred Course of Treatment despite High Cost
The key treatment methods for Kaposi sarcoma include immunotherapy, chemotherapy, and antiretroviral therapy. Of these, the segment of antiretroviral therapy emerged at the leading segment owing to the high incidence rate of AIDS-related Kaposi sarcoma. The segment will continue to grow at an encouraging pace in the next few years as well.
Over the report’s forecast period, however, the segment of chemotherapy is expected to exhibit growth at the most promising pace, chiefly owing to the high treatment cost and the high preference given to the treatment method by immunocompetent patients. Some of the most popular chemotherapy drugs in the market are vincristine, docetaxel, paclitaxel, bleomicin, daunorubicin, and liposomal doxorubicin. Although the high preference to this treatment method, its high cost could emerge as a key deterrent to patient population across some regions, especially across developing and less developed economies across Asia Pacific and Africa, limiting its growth prospects.
North America to Retain Dominance in Global Market despite a Low Rate of Prevalence of Kaposi Sarcoma
From a geographical standpoint, North America is presently the leading contributor of revenue to the global Kaposi sarcoma market. The region holds a leading position in the global market owing to the presence of some of the world’s leading vendors in the field and the rising costs of drugs. The North America market for Kaposi sarcoma also benefits from the high rate of diagnosis of the condition and the easy availability of drugs. The region features a low incidence rate of the disease but has been witnessing a shortage in supply of drugs required for its treatment, leading to a wide demand-supply gap and subsequently significant scope of growth.
Over the report’s forecast period, the market is expected to witness the most promising rate of growth in the Middle East and Africa region. The region is expected to lead to the heightened demand for Kaposi sarcoma drugs owing to the high rate of incidence of the disease. The high rate of prevalence of HIV/AIDS is and thus the increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa is also a key driving factor, along with the fact that awareness among people is low.
Some of the leading players operating in the immensely consolidated vendor landscape of the global Kaposi sarcoma market are Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co.
Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the market based on type of treatment, distribution channel, and geography.
The report is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of major Kaposi sarcoma therapies in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each treatment method, distribution channel, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each treatment method was calculated by considering number of patients, average cost of the drugs, trends in the industry, distribution channel trends, and adoption rate of therapy across all the geographies. The revenues generated from services, including surgery and radiation therapy were calculated based on the costs and average number of procedures.
The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that influence the Kaposi sarcoma market in the current and future scenario. The report provides the list of drugs in various stages of clinical trials, which are expected to shape the future course of the market, through pipeline analysis. The report also provides value chain analysis of the market that describes the sequence of activities from drug manufacturing to the final destination, which is the end user.
Market share analysis is provided to highlight percentage share of the major players operating in the market. All these factors will help market players to decide business strategies and plans to strengthen their position in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Market forecast for major countries in these regions have also been provided for the forecast period.
In addition, this report includes a list of recommendations to aid new entrants and established players in taking strategic initiatives to strengthen their presence in the market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the Kaposi sarcoma market report are Bristol - Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.)
The global Kaposi Sarcoma market has been segmented as follows:
- Kaposi Sarcoma Market, By Type of Treatment
- Liposomal Anthracyclines
- Kaposi Sarcoma Market, By Distribution Channel
- Cancer Research Institutes
- Multispecialty Clinics
- Ambulatory Surgical Centers
- Kaposi Sarcoma Market, By Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- North America